NCT07565727 Cardiometabolic Disease and Substrate Metabolism
| NCT ID | NCT07565727 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Tennessee Graduate School of Medicine |
| Condition | Preeclampsia |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-12-10 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-12-10 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.
Eligibility Criteria
Inclusion Criteria: * Age 18-45 * Any pre-pregnancy BMI * At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines * Willingness to adhere to aspirin therapy * Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc. * Gestational age at enrollment \<18 weeks * Ability to speak, read, and communicate via English Exclusion Criteria: * Type 2 Diabetes Mellitus * Type 1 Diabetes Mellitus * Current gestational diabetes mellitus * Current/active platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura/ITP, thrombotic thrombocytopenic purpura/TTP, von Willebrand disease, etc.) * Thrombophilia * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.) * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.) * Current or recent use of steroids * Current use of prophylactic or therapeutic anticoagulation * Medical contraindication to aspirin therapy * Molar pregnancy * Renal disease * Inability or unwillingness to give informed consent * Current psychiatric illness/social situation that would limit compliance with study requirements, as determined by the principal investigators
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07565727 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07565727 currently recruiting?
Yes, NCT07565727 is actively recruiting participants. Contact the research team at jmaples1@utmck.edu for enrollment information.
Where is the NCT07565727 trial being conducted?
This trial is being conducted at Knoxville, United States.
Who is sponsoring the NCT07565727 clinical trial?
NCT07565727 is sponsored by University of Tennessee Graduate School of Medicine. The trial plans to enroll 50 participants.